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Abstract 
Recent treatment for type 2 diabetes mellitus (T2DM) has included glucagon-like peptide-1 receptor agonist 
(GLP-1 RA), indicating clinical efficacy for better glucose variability. Subjects were seven patients with T2DM 
associated with the obese tendency. Their average age was 63.8 ± 21.7 years old (5 males, 2 females) who received 
a new administration of GLP-1 RA (Mean ± standard deviation). For GLP-1 RA, dulaglutide (TRULICITY R, single-
dose pen) was administered by subcutaneous injection 0.75 mg once a week. Basal data at 0 month revealed that 
body weight 76.0 ± 11.6 kg, body mass index (BMI) 29.2 ± 11.6, blood C-peptide immunoreactivity (CPR) 2.68 ± 
0.49 ng/mL, respectively. After the intervention of dulaglutide, decreased value of BMI for 3 and 6-9 months was 
0.78 ± 0.45 and 1.16 ± 0.85, and HbA1c for 3 and 6-9 months was 1.60 ± 1.52% and 2.01 ± 1.44%, respectively. 
Though these cases have various complications besides T2DM, they showed clinical effects of weight reduction 
and lowering blood glucose. Diabetic treatment for current cases would suggest that GLP-1 RA would be effective 
in various situations such as a super-aged patient, medical practice in the remote area, family care and visiting 
nursing. 
 
Introduction 
     Diabetes has been increasing steadily in developing 
and also developing countries [1]. It is a crucial 
disease that must be resolved all over the world today. 
It influences much in the wide range of fields, 
medically, socially and economically. Because of 
developing macroangiopathy and microangiopathy, 
diagnosis and treatment are required from various 
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viewpoints [2]. 
 
    The International Diabetes Federation (IDF), the 
American Diabetes Association (ADA) and the 
European Association for the Study of Diabetes (EASD) 
have compiled standard guidelines for their 
management [3]. Among them, one of the recent 
attention is the diet. There are some known kinds of 
diet methods, which are Calorie Restriction Diet 
(CRD), Low Carbohydrate Diet (LCD), Mediterranean 
diet (MD) and others. These nutritional therapies have 
been reported and discussed for long. Thus, the 
comparison between CRD and LCD has been 
particularly in focus until now [4,5]. 
 
    LCD was originally proposed by Atkins et al., in 
which short-term weight loss and blood sugar 
improvement effects have been reported [6]. After 
that, comparisons were made for diets such as LCD, 
CRD, MD, etc. and the clinical usefulness of LCD was 
reported by Shai et al. [7]. These are the ongoing 
clinical studies of LCD in the North American and the 
European region. 
 
On the other hand, in Japan, a group of authors 
started LCD and have developed in the clinical practice 
and research field. Initially, Ebe et al. have reported 
LCD method for the first time [8]. Consequently, by 
applying LCD at the clinical situation, the research 
group proposed petite-LCD, standard-LCD and super-
LCD as three types of LCD [9]. As a result, many 
patients and general people can apply LCD for medical 
treatment and health promotion. Movement for LCD 
has been spread in the activities of Japan LCD 
Promotion Association (JLCDPA) through more books 
and workshops. Furthermore, in clinical studies, we 
have reported elevated blood ketone bodies in the axis 
of fetuses, placentas, neonates and pregnant women, 
and reported the physiological important role of 
ketone bodies [10]. 
 
When LCD is actually applied to diabetic patients, 
the average blood glucose and mean amplitude of 
glycemic excursions (MAGE) could be decreased. 
Consequently, the profile of blood glucose will be 
clinically improved, indicating the efficacy of LCD. In 
fact, however, there are not so many diabetic patients 
who showed successful results by LCD due to various 
reasons. The authors have clinical experience for 
many diabetes patients, with lots of struggled 
management among them. 
 
    One of the developments for diabetic research has 
been the presence of intestine secretion insulin 
(INCRETIN). Consequently, gastric inhibitory 
polypeptide (GIP) was identified by purification of 
intestinal hormone and glucagon-like peptide-1 (GLP-
1) indicating the action of the incretin action was 
reported [11]. After that, several studies showed the 
functional role and mechanism of GLP-1 [12]. Its 
physiological role includes various functions, such as 
inhibiting glucagon secretion, stimulating insulin 
secretion, increasing glucose production and glucose 
uptake in the liver, promoting glucose uptake and 
glycogen production in muscle, reducing food intake 
for the central nerve system and delay of gastric 
emptying [13]. For the treatment of patients with 
diabetes, GLP-1 receptor analogue (GLP-1 RA) and 
also Dipeptidyl peptidase-4 (DPP-4) inhibitor have 
been recent topics associated with effective therapy. 
 
Especially, GLP-1 RA has been known as highly 
effective anti-hyperglycemic agent with low risk of 
hypoglycemia and expectation for body weight 
reduction [14]. Several kinds of GLP-1 RA have been 
used in diabetic medical practice, and their efficacy 
has been recognized so far. 
 
From mentioned above, authors have experienced 
the cases where GLP-1 RA has been administered to a 
diabetic patient who showed rather less beneficial 
efficacy from LCD method for nutritional therapy. 
Among them, we report and discuss here from 
various points of view. 
 
Patients and Methods 
The subjects enrolled in this study were 7 patients 
with type 2 diabetes mellitus (T2DM) associated with 
obese tendency. Their average age was 63.8 ± 21.7 
years old (29 to 89 years, 5 males, 2 females) who 
received a new administration of GLP-1 RA at our 
clinic after January 201X. Average observation period 
(day) was 223 ± 175 days (90-598). In 6 cases out of 7 
cases, DPP-4 inhibitor was discontinued and GLP-1 RA 
 Manuscript no: ASJBCCR-2-S1-007 Volume: 2     Special Issue: 1 40 
Asp Biomed Clin Case Rep 
 
Special Issue: Case Report Low Carbohydrate Diet 
Citation: Shirakawa M, Kanamoto Y, Nagaoka H, et al., “Diabetic cases controlled with low carbohydrate diet (LCD) and 
GLP-1 receptor agonist (GLP-1 RA)”, Asp Biomed Clin Case Rep, vol.2, no.s1: 38-46, 2019. 
 
was started. In one case, GLP-1 RA was started from 
the beginning. 
 
For the administration of GLP-1 RA, dulaglutide 
was used, where the trade name is TRULICITY R with 
subcutaneous injection 0.75 mg (single-dose pen) 
[15]. It was administered once a week once. In the 
case of treatment for sulfonylurea agent, the dose was 
half of the standard. Before the initiation of GLP-1 
agent, body weight, blood glucose, HbA1c value and 
blood C-peptide immunoreactivity (CPR) were 
measured. 
 
As to the basal data, the mean pre-dose body 
weight was 76.0 ± 11.6 kg, the pre-dose mean BMI 
was 29.2 ± 11.6, and the pre-dose mean blood CPR 
(ng/ml) 2.68 ± 0.49. The data of mean ± standard 
deviation, minimum and maximum were shown in 
Table-1. There were no cases of discontinuation of 
administration due to serious reverse effects and 
other problems by the end of the observation period. 
 
Table-1: Summary of basal data in 7 subjects 
  Mean ± SD Min - Max 
Age（years old） 63.8 ± 21.7 29 - 89 
Observation Period
（day） 
223 ± 175 90 - 598 
Body Weight (kg) 76.0 ± 11.6 65.8 - 98.8 
BMI 29.2 ± 11.6 25.1 - 39.1 
C-peptide (ng/ml) 2.68 ± 0.49 1.7 - 3.3 
 
Results 
    The decreased value of BMI in the observation 
period for 6-9 months was 1.16 ± 0.85. Among 
them, the mean reduction value for 3 months was 
0.78 ± 0.45 (Table-2). On the other hand, the average 
HbA1c reduction value (%) in the observation period 
for 6-9 months was 2.01 ± 1.44 %. Similarly, the 
mean HbA1c reduction value (%) for three months 
was 1.60 ± 1.52 % (Table-2). The data of minimum 
and maximum are also included in Table-2. 
 
 
Table-2: Summary of results in 7 subjects 
  Mean ± SD Min - max 
Decreased value of BMI 
for 6-9 months (kg/m2) 
1.16 ± 0.85 -2.3 
Decreased value of BMI 
for 3 months (kg/m2) 
0.78 ± 0.45 0.2 - 1.6 
Decreased value of HbA1c 
for 6-9 months (%) 
2.01 ± 1.44 0.2 - 3.3 
Decreased value of HbA1c 
for 3 months (%) 
1.60 ± 1.52 0.4 - 3.2 
 
Case Presentation 
There are 7 patients with T2DM associated with 
various complications and situations, which were 
provided GLP-1 RA. These cases are described in the 
following. 
 
Case-1: 
The patient is an 89-year-old man who presents 
with chronic obstructive pulmonary disease (COPD) as 
a co-morbid medical problem. He had a cerebral 
infarction 17 years ago and has right hemiplegia and 
motor aphasia since then. He was admitted for 
pneumonia and rhabdomyolysis 5 years ago. 
 
As a present history, he has given visiting home care 
due to COPD and heart failure for 5 years. He showed 
weight gain and exacerbated diabetes, leading to lower 
extremity arterial occlusion due to refractory right foot 
cellulitis. A strong intervention for glycemic control 
was required and was increased to 4 mg of 
glimepiride. On regular visits in January 201X, he 
showed the following status: height 156 cm, weight 
61.0 kg, BMI 25.1, skin ulcers, right hemiplegia, and 
motor aphasia. Laboratory data revealed fasting blood 
glucose (FBG) 181 mg / dl, HbA1c 9.4%, and blood C-
peptide 3.3 ng / ml. 
 
Diagnoses were 1) T2DM, 2) Congestive heart 
failure, 3) Obstructive arteriosclerosis and intractable 
right foot cellulitis, 4) Cerebral infarction, 5) Obesity. 
We had taught diet therapy including LCD and/or 
CRD, but he cannot obey or continue it. Even though 
he has given visiting rehabilitation, his weight was 
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stable because of frequent snacks and less exercise in 
his daily life. 
 
Then, his treatment changed by reduced 
glimepiride from 4 mg to 2 mg/day, discontinued 
DPP-4 inhibitor and administration of a GLP-1 RA. It 
can reduce severe hypoglycemia, heart failure, and 
body weight. After 7 months, body weight was 
decreased from 61.0 kg to 56.6 kg, and glycemic 
control was also significantly improved to HbA1c 
6.1%. After that, the glimepiride was reduced to 1.5 
mg/day, and the weight became stable at 56.0 Kg and 
HbA1c 6.1%. 
 
Case-2: 
The patient is a 29-year-old woman, who also has 
schizophrenia as a complication. Obesity and diabetes 
were originally present. After pregnant and birth, she 
had become uncontrolled diabetic states because of 
lack of exercise and inadequate meal habit. 
Consecutively, she was admitted for the treatment of 
schizophrenia, and treated by oral metformin + DPP-
4 inhibitor. Her status was 159 cm in height, 98.8 kg 
in weight, and BMI 39.1. Laboratory tests showed that 
FBG 237 mg/dl, HbA1c 11.4%, blood C-peptide 2.9 
ng/ml. 
 
From these diabetic situations, conventional 
treatment was considered to be difficult. She could 
not obey diet therapy of LCD or CRD, and then a GLP-
1 receptor agonist was started from January 201X. She 
had a weight reduction of 1.0 Kg, HbA1c 1.0% 
decrease with gradual efficacy of GLP-1 RA for 3 
months. After 5 months, the weight dropped to 97 kg 
and HbA1c was 10.0%. She had been admitted to the 
hospital for schizophrenia and diabetes. Her general 
status has been improved, and then she was 
discharged. At present, the body weight was 
decreased to 93.2 kg, and HbA1c 8.2% with recently 
stable clinical course. 
 
Case-3: 
The patient is a 64-year-old male, who has some 
complications such as cerebral infarction with three 
times of events, hypertension, dyslipidemia and 
chronic kidney disease (CKD). As a medical history, 
insulin has been used before the recurrence of 
cerebral infarction. After relapse, he was referred to 
our hospital and controlled with oral medicine. He 
developed third cerebral infarction, and after 
discharge, he has been treated with anti-diabetic oral 
agents 2 years ago. His diet therapy was incomplete 
and lack of exercise due to paralysis has led him to 
rather poor diabetic control. 
    His physical examination included 170 cm in height, 
77.7 kg in weight, 26.9 in BMI. Laboratory exams 
showed FBG 208 mg / dl, HbA1c 8.9%, blood C-
peptide 3.0 ng/ml at the start of administration for 
GLP-1 agonist (dulaglutide). 
 
As the progress course after diagnosis, his diet 
therapy was started as a combination of LCD and CRD. 
Furthermore, glimepiride was reduced by half, DPP-4 
inhibitor was discontinued, and dulaglutide was 
started. At 3 months after initiation, there was a 
weight loss of 2.2 kg and HbA1c decreased by 0.5%. At 
7 months for dulaglutide, the body weight dropped to 
75.9 kg and HbA1c 7.8%. He has had no remarkable 
adverse effects during these treatments. 
 
Case-4: 
The patient is a 68-year-old woman, and 
complications are hypertension, bilateral osteoarthritis 
(OA), and spinal stenosis with low back pain. As a 
present history, she has been diabetic and treated for 7 
years. Two operations were performed for lumbar 
spinal stenosis, but lumbar disc herniation has been 
still found at present. She was introduced to our clinic 
because she must take care of her sick family at home 
and it is difficult to visit a large hospital in a remote 
area. After that, she has gained weight from lack of 
exercise and became a more uncontrolled diabetic 
status. 
 
Her status was 152 cm in height, 68.5 kg in body 
weight, 29.6 in BMI. Her diabetes related tests at the 
start of administration showed that FBG 182 mg/dl, 
HbA1c 8.1%, and C-peptide in blood 2.7 ng/ml. The 
clinical course after diagnosis, she was indicated to 
continue standard LCD. Clinical progress revealed 1.4 
kg weight reduction and HbA1c 0.6% decrease of 
HbA1c in two months. At 3 months, her weight was 
0.4 kg reduced and her HbA1c was 0.4% decreased. 
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After 6 months, the body weight increased to 68.9 kg 
with HbA1c 7.9%. Consequently, more appropriate 
therapeutic interventions are needed in the future. 
 
Case-5: 
The patient is a 35-year-old male who has been a 
smoker with dyslipidemia. As to his family history, 
grandfather and mother had T2DM, and mother had a 
myocardial infarction. He has been obese and diabetic 
for a long year. After educational hospitalization for 
diabetes, he has introduced to our clinic for successive 
treatment for diabetes three years ago. Consequently, 
oral medication of DPP-4 inhibitor and SGLT-2 RA 
were continued, associated with metformin later in 
our clinic. However, his adherence to medication has 
been very poor, and the glycemic control has become 
worsened. 
 
Currently, his status has been that height 170 cm, 
weight 79.8 kg, BMI 27.6, FBG 279 mg/dl, HbA1c 
11.7% and blood C-peptide 2.3 ng/ml. He was advised 
to continue adequate diet therapy with LCD and CRD. 
Regarding the treatment for diabetes, a DPP-4 
inhibitor was discontinued, and GLP-1 RA was 
started. At 2 months, he had weight reduction of 2.3 
kg and a 2.8% decrease of HbA1c value. At 3 months, 
the weight loss was 2.4 kg, and HbA1c decrease was 
4.1%. After 4 months, his body weight was 75.5 kg 
and HbA1c was 7.4%, with gradually improved 
diabetic state.  
 
Case-6: 
The patient is a 79-year-old male with 
complications of dementia, atrial fibrillation, and 
chronic heart failure. He had been originally not 
obesity for years and treated for atrial fibrillation and 
chronic heart failure. The patient's wife has been 
administering long-acting insulin with his support to 
some extent previously. However, he has been 
gradually with dementia state since 5 years ago. He 
shows the habit of overeating in a hidden situation 
from his family. Thus, He became obese due to lack of 
exercise and was recently diagnosed with T2DM. 
 
His physical examination revealed that height 165 
cm, weight 81.0 kg, and BMI 29.8. The diabetes 
related tests included FBG 150 mg/dl, HbA1c 7.7% and 
C-peptide 2.9 ng/ml. Diet therapy seemed to be 
actually difficult because of dementia. In response to 
the administration of GLP-1 RA, body weight was 
decreased by 1 kg and HbA1c was decreased by 0.3% 
in one month. There were 1.7 kg of weight loss, HbA1c 
0.6% decrease in 2 months. At 3 months the diabetic 
situation was that the weight was regained to 80.7 kg, 
but HbA1c was improved to 6.9% with a moderate 
stable condition.  
 
Case-7: 
The patient is an 83-year-old male with type 2 
diabetes, with the complication of hypertension and 
osteoarthritis (OA) on both knees. He has been treated 
for these diseases for nine years. A few years ago, he 
was hospitalized with a teaching education for 
diabetes and has been receiving DPP-4 inhibitor and 
sulfonylurea agent until now. Since he is living alone, 
however, he cannot continue adequate diet therapy, 
such as many snacks and lack of exercise due to OA on 
both knees. As a result, obesity worsened his QOL and 
ADL, then the diabetes control has become in poor 
condition. 
 
His physical examination showed 158 cm in height, 
65.8 kg in weight, BMI 26.4, and diabetes related tests 
showed that FBG 229 mg/dl, HbA1c 9.0%, and serum 
C-peptide 1.7 ng/ml. He cannot obey diet therapy, 
because he wanted to eat as he likes. One month after 
starting GLP-1 RA, body weight was decreased by 2.8 
kg, and HbA1c was decreased by 0.3%. At two months, 
body weight decreased by 2.8 kg, HbA1c decreased by 
0.6%. After 3 months, his weight was reduced to 62.0 
kg, HbA1c 7.8%, and his clinical course has been better 
and stable.  
 
  As mentioned above, related data for 7 cases treated 
with GLP-1 RA are summarized in Table-3. There was 
a tendency of weight reduction and decreased HbA1c 
value in 3 months.  
 
Discussion 
Recently, the new anti-hyperglycemic agent has 
been developed, which is GLP-1 RA. It has a 
remarkable efficacy and safety profile distinct from 
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other anti-diabetic agents [16]. GLP-1 has been 
reported to have several functions as follows: 
stimulating insulin secretion, inhibiting glucagon 
secretion, promoting glucose production and glucose 
uptake in the liver, increasing glucose uptake and 
glycogen production in skeletal muscle, decreasing 
food intake for the central nerve, delay of gastric 
emptying and so on [14]. 
From the physiological point of view, it is 
meaningful to compare the functions of three kinds of 
related hormones, which are GLP-1, gastric inhibitory 
polypeptide (GIP) and glucagon. These factors seem 
to have various effects on several organs, such as the 
brain, gastrointestinal tract, pancreas, liver, adipose 
tissue and bone [17]. Among them, GLP-1 and GIP is a 
pair of two incretin hormones, which are secreted 
from the gut for the ingestion of nutrients. Those two 
hormones can increase insulin secretion and also 
improve the glucose fluctuation after a meal [18]. 
GLP-1 and GIP both show the influence of decreased 
food intake for the brain. 
 
In contrast, there seem to show the opposite effects 
in other organs. For the glucagon secretion from the 
pancreas, GLP-1 shows suppressive effect, and GIP 
shows stimulating effect. For bone metabolism, GLP-1 
seems to have a stimulating effect on bone formation, 
and GIP seems to have suppressive effect for bone 
resorption [17].  
 
One of the GLP-1 RA is dulaglutide, which is given 
only once a week. Some beneficial points include easy 
injection procedure, high blood glucose improving the 
effect and low frequency of antibody appearance. 
Further, it is practical and easy for patients who show 
cognitive impairment or poor compliance and require 
daily care and others. Regarding the clinical efficacy, 
it showed a dose-dependent reduction in HbA1c and 
acceptable safety profile in the randomized, double-
blind, placebo-controlled study [19]. 
 
There is a reason that dulaglutide can be injected 
once a week. Its degradation has been delayed 
because of DPP-4 inhibition in the blood. The increase 
in molecular weight also reduces the absorption rate 
and clearance after the injection. Consequently, the 
half-life of blood concentration would be extended to 
4-5 days, and thus its concentration in the blood would 
be rather maintained for one week [13]. From these 
situations, long-acting dulaglutide may bring better 
adherence and prevent the deterioration of Health-
related Quality of Life (HRQOL). 
 
There was a report concerning the comparison 
between once-weekly dulaglutide and once-daily 
liraglutide. On 52-week investigation, two groups of 
dulaglutide 0.75mg / week and Liraglutide 0.9mg/day 
showed -1.39% and -1.19%, respectively, with slight 
superiority in the former [20]. Another study in 
western countries showed that they use the dose as 
twice value. From the paper on AWARD-6, two groups 
of dulaglutide 1.5mg/week and liraglutide 1.8mg/day 
at 26 weeks have the efficacy of decreasing of HbA1c. 
The results were equivalent that the former was -
1.42% and the latter was -1.36% [21]. 
 
    The effect of dulaglutide was investigated in 855 
patients with T2DM [22]. There were categorized into 
4 groups by the age (border 65 years old) and BMI 
(border 25) as follows: 1) young and low-BMI, 2) 
young and high-BMI, 3) elderly and low-BMI, 4) 
elderly and high-BMI. The mean changes from 
baseline in HbA1c and body weight at 26 weeks were 
1) -1.69% and -0.29 kg, 2) -1.48% and -0.09kg, 3) -
1.68% and -0.20kg, 4) -1.72% and -0.26kg, 
respectively. Thus, dulaglutide improved HbA1c values 
regardless of the value of age and BMI.   
 
Diabetes has been increasing anywhere, in urban 
and also remote areas. The first author has continued 
walk-in clinic for long years in rather remote area. 
There are several clinical problems with the initiation 
of injection therapy for diabetes. They include i) 
difficult staff education, ii) rejection of treatment by 
injection from patients, and iii) necessary assistance 
by families [23]. In particular, from the point of 
primary care medicine, management may be difficult 
in sparsely populated areas due to lack of manpower. 
 
On the other hand, dulaglutide is convenient for 
only once-weekly administration. Its advantage would 
include excellent glycemic control, a constant dose of 
0.75mg, and simple useful device [14]. Therefore, we 
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could easily started dulaglutide for 7 cases in a 
sparsely populated area. There has been recently a 
clinical situation of injection for drug administration 
in the orthopedic region. Authors and staffs have lots 
of experiences to teach self-injection of teriparatide 
(ForteoR subcutaneous injection kit 600μg) for 
osteoporosis [24]. Therefore, it was rather easy to 
introduce and show how to manage it safely and 
efficiently. 
 
As regard to 7 cases in this study, diet therapy 
including LCD and/or CRD was not so successful from 
bio-, psycho- and social points of view. It was 
necessary to adjust the dose of dulaglutide and other 
medicine [19]. In other words, the DPP-4 inhibitor 
was discontinued and GLP-1 preparation was 
administered except for case-6. The dose of 
sulfonylurea agent was reduced to half in cases 1, 3, 4 
and 7. As a result, weight reduction and decreased 
HbA1c were found except for case-4 (Table-3). In 
particular, case-1 was a home-based case, and then its 
management was difficult due to various 
complications. There were anorectic effect and 
suppression of deterioration of heart failure due to 
Table-3: Summary of 7 cases treated with GLP-1 RA (duraglutide) 
Cases 
BMI at 0 
month 
CPR (ng/ml) At 0 
month 
CPI at 0 
month 
Weight (kg) 
0→3 month 
HbA1c (%) 0→3 
month 
Case-1: 89 M 25.1 3.3 1.82 61.0→57.5 9.4→6.2 
Case-2: 29 F 39.1 2.9 1.22 98.8→97.8 11.4→10.4 
Case-3: 64 M 26.9 3 1.44 77.7→75.5 8.9→8.4 
Case-4: 68 F 29.6 2.7 1.44 68.5→68.1 8.1→7.7 
Case-5: 35 M 27.6 2.3 0.82 79.8→77.4 11.7→7.6 
Case-6: 79 M 29.8 2.9 1.9 81.0→80.7 7.7→6.9 
Case-7: 83 M 26.4 1.7 0.7 65.8→62.0 9.0→7.8 
BMI: Body Mass Index, CPR: C-peptide Radioactivity  
CPI (C-peptide index) = CPR×100 / FBG (fasting blood glucose)  
 
weight loss in case-1, suggesting clinically significant 
usefulness [25,26].  
Another notable effect would be the effectiveness 
for mental diseases associated with obesity. 
Conventionally, administration reports for dementia 
have been found occasionally, but single-agent 
administration is rare like case-6 [27]. Furthermore, 
there are limited cases of continuing at home in 
schizophrenia such as case-2. In these cases, 
treatment on GLP-1 RA was successful once a week 
[38]. In fact, however, various supports from family 
care and home-visit nursing seem to be essential. 
 
On the other hand, case-4 showed weight gain with 
inadequate control even after using dulaglutide. It is 
necessary to review lifestyle guidance and to consider 
additional administration of anti-diabetic agents as 
future issues. In particular, authors would 
recommend rehabilitation for pain relief, contracture 
prevention, promote exercise habits, and improve the 
future care environment. 
 
    As mentioned above, dulaglutide was administered 
to diabetes, and medical and academic discussion was 
described in this report. To summarize the important 
points, 
I. Dulaglutide was given to super-elderly patients 
with T2DM on home care, leading to weight 
reduction and better glycemic control.  
II. From the successful result of dulaglutide therapy, 
we developed GLP-1 RA treatment to other 
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outpatients in order to improve the quality of 
diabetic care in remote areas. 
III. Depending on the cases, various supports would 
be essential such as family care and visiting 
nursing. 
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